2022
DOI: 10.1016/j.jpba.2021.114402
|View full text |Cite
|
Sign up to set email alerts
|

Development and validation of an HPLC-MS/MS method for the quantification of the anti-leishmanial drug miltefosine in human skin tissue

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
9
0

Year Published

2022
2022
2024
2024

Publication Types

Select...
7

Relationship

1
6

Authors

Journals

citations
Cited by 12 publications
(18 citation statements)
references
References 18 publications
0
9
0
Order By: Relevance
“…These PK studies improved formulation strategies for amphotericin B and improved therapeutic dosing regimens for all antileishmanial drugs by characterizing exposure and exposure‐response relationships of the treatments. There is an increased interest to involve target‐site PK data coupled to classical blood matrices to gain more information on exposure‐response relationships and distribution of drugs to their respective site of target (Rizk et al, 2017; Roseboom, Rosing, et al, 2020; Roseboom, Thijssen, Rosing, Alves, Mondal, et al, 2022; Xue et al, 2012). Considering future target‐site antileishmanial PK studies, the development and validation of bioanalytical methods for the quantification of antileishmanial drugs in human skin tissue (CL and PKDL), spleen, liver, and bone marrow (VL) and PBMCs (leishmaniasis in general) will gain prominence.…”
Section: Discussionmentioning
confidence: 99%
See 2 more Smart Citations
“…These PK studies improved formulation strategies for amphotericin B and improved therapeutic dosing regimens for all antileishmanial drugs by characterizing exposure and exposure‐response relationships of the treatments. There is an increased interest to involve target‐site PK data coupled to classical blood matrices to gain more information on exposure‐response relationships and distribution of drugs to their respective site of target (Rizk et al, 2017; Roseboom, Rosing, et al, 2020; Roseboom, Thijssen, Rosing, Alves, Mondal, et al, 2022; Xue et al, 2012). Considering future target‐site antileishmanial PK studies, the development and validation of bioanalytical methods for the quantification of antileishmanial drugs in human skin tissue (CL and PKDL), spleen, liver, and bone marrow (VL) and PBMCs (leishmaniasis in general) will gain prominence.…”
Section: Discussionmentioning
confidence: 99%
“…Considering future target‐site antileishmanial PK studies, the development and validation of bioanalytical methods for the quantification of antileishmanial drugs in human skin tissue (CL and PKDL), spleen, liver, and bone marrow (VL) and PBMCs (leishmaniasis in general) will gain prominence. Quantification in skin tissue was to date published only for amphotericin B (Roseboom, Thijssen, Rosing, Alves, Sundar, et al, 2022), miltefosine (Roseboom, Thijssen, Rosing, Alves, Mondal, et al, 2022), and pentavalent antimonials (da Justa Neves et al, 2009) and is expected to contribute to future antileishmanial target‐site PK studies in CL and PKDL patients. Quantification in liver was described for pentavalent antimonials (Lyon et al, 2002; Patriarca et al, 1999).…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…Nowadays, and transversal to several fields of science-including medicine, chemistry, pharmacy, and other related fields, high resolution chromatographic techniques (HRCT) and mass spectrometry (MS), has evolved as one of the most valuable analytical tools available to modern scientists allowing a deep and comprehensive knowledge on structural elucidation of unknown substances [133], quality control of drugs [134], clinical [135], environmental [136], food control [137], and forensic analytes [138], providing qualitative as well as quantitative information for a broad variety of compound classes. Other applications include inorganic chemical analysis, geochronology [139], reaction kinetics [140], determination of thermodynamic parameters and ion-molecule reactions [141].…”
Section: Advanced Mass Spectrometry and Chromatographymentioning
confidence: 99%
“…They showed that there is a considerable difference in the proteome profiles of drug sensitive and drug resistance groups, therefore highlighting the possibilities of the development of therapeutic antileishmanials [ 88 ]. Roseboom and his co-workers showed that HPLC-MS/MS could be successfully used for the quantification of the anti-leishmanial drug miltefosine in human skin tissue for its potential efficacy [ 89 ]. Nevertheless, the pharmacokinetic studies, which are key to the later development and validation of drugs, have also been conducted for leishmaniasis [ 90 ].…”
Section: Advanced Proteomics Approaches In Leishmaniasis Drug Discoverymentioning
confidence: 99%